A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China

BACKGROUND: Breast cancer patients of American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) Group 2 were all HER2-negative according to the 2018 guideline, not HER2-positive as defined in the 2013 guideline. METHODS: We aims to elucidate the unique clinicopatholog...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shuling, Lv, Hong, Li, Anqi, Li, Ming, Zhong, Siyuan, Lu, Hongfen, Zhou, Xiaoyan, Bai, Qianming, Yang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875391/
https://www.ncbi.nlm.nih.gov/pubmed/36698078
http://dx.doi.org/10.1186/s12885-023-10531-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875391/
https://www.ncbi.nlm.nih.gov/pubmed/36698078
http://dx.doi.org/10.1186/s12885-023-10531-z

Ejemplares similares